Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer

详细信息    查看全文

• 作者：T. Shimizu ; Y. Nakagawa ; N. Takahashi ; S. Hashimoto
• 关键词：Thymidylate synthase ; Gene amplification ; Pemetrexed ; Fluorescence in situ hybridization ; Immunohistochemistry
• 刊名：Clinical and Translational Oncology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：18
• 期：1
• 页码：107-112
• 全文大小：619 KB
• 参考文献：1.Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 2009;66:141–9.PubMed CrossRef
  2.Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(19):3217–24.PubMed CrossRef
  3.Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, et al. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999;127:1777–86.PubMed PubMedCentral CrossRef
  4.Flynn J, Berg RW, Wong T, van Aken M, Vincent MD, Fukushima M, et al. Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther. 2006;5:1423–33.PubMed CrossRef
  5.Lin SB, Ts’o PO, Sun SK, Choo KB, Yang FY, Lim YP, et al. Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment. Mol Pharmacol. 2001;60:474–9.PubMed
  6.Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116–23.PubMed
  7.Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol. 1999;26(2 Suppl 6):42–7.PubMed
  8.Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethy l]benzoyl]-l -glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem. 1992;35:4450–4.PubMed CrossRef
  9.Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. AnticancerRes. 1999;19:437–43.
  10.Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol. 2003;66:431–8.PubMed CrossRef
  11.Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011;104(10):1594–601.PubMed PubMedCentral CrossRef
  12.Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, et al. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res. 2012;32:4589–96.PubMed
  13.Nakagawa Y, Shimizu T, Takahashi N, Hashimoto S. Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients. Mol Clin Oncol. 2013;1:411–7.PubMed PubMedCentral
  14.Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27(8):1323–33.PubMed CrossRef
  15.Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.PubMed CrossRef
  16.Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol. 1996;14:176–82.PubMed
  17.Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298–304.PubMed
  18.Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 1999;19:5621–6.PubMed
  19.Takamura M, Nio Y, Yamasawa K, Dong M, Yamaguchi K, Itakura M. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs. 2002;13:75–85.PubMed CrossRef
  
• 作者单位：T. Shimizu (1)
  Y. Nakagawa (1)
  N. Takahashi (1)
  S. Hashimoto (1)
  
  1. Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, 30-1, Oyaguchi-Kamichou, Itabashi-ku, Tokyo, 173-8610, Japan
  
• 刊物主题：Oncology;
• 出版者：Springer Milan
• ISSN：1699-3055

文摘

Background Thymidylate synthase (TYMS) expression in lung cancer tissue affects the therapeutic efficacy of pemetrexed (PMT). TYMS protein expression is primarily assessed using immunohistochemistry (IHC), but this method is not suitable for accurate quantitative analysis. It is not known whether the analysis of TYMS gene copy number using fluorescence in situ hybridization (FISH) is a useful method for assessment of TYMS expression.